A new trading day began on Friday, with Verona Pharma Plc ADR (NASDAQ: VRNA) stock price up 4.05% from the previous day of trading, before settling in for the closing price of $27.64. VRNA’s price has ranged from $11.39 to $30.73 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -39.77% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged -188.89%. With a float of $62.79 million, this company’s outstanding shares have now reached $80.44 million.
In an organization with 79 employees, it is important to assess its efficiency.
Verona Pharma Plc ADR (VRNA) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Verona Pharma Plc ADR is 22.56%, while institutional ownership is 62.24%. The most recent insider transaction that took place on Sep 11 ’24, was worth 2,254,320. In this transaction President and CEO of this company sold 600,000 shares at a rate of $3.76, taking the stock ownership to the 15,250,704 shares. Before that another transaction happened on Sep 11 ’24, when Company’s Chief Financial Officer sold 600,000 for $3.76, making the entire transaction worth $2,254,080. This insider now owns 14,339,688 shares in total.
Verona Pharma Plc ADR (VRNA) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -188.89% per share during the next fiscal year.
Verona Pharma Plc ADR (NASDAQ: VRNA) Trading Performance Indicators
Here are Verona Pharma Plc ADR’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 8.61.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.56, a number that is poised to hit -0.06 in the next quarter and is forecasted to reach -0.20 in one year’s time.
Technical Analysis of Verona Pharma Plc ADR (VRNA)
Let’s dig in a bit further. During the last 5-days, its volume was 0.87 million. That was inferior than the volume of 0.91 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 19.70%. Additionally, its Average True Range was 1.50.
During the past 100 days, Verona Pharma Plc ADR’s (VRNA) raw stochastic average was set at 89.81%, which indicates a significant increase from 48.56% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 46.10% in the past 14 days, which was lower than the 66.31% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $26.01, while its 200-day Moving Average is $18.75. However, in the short run, Verona Pharma Plc ADR’s stock first resistance to watch stands at $29.40. Second resistance stands at $30.04. The third major resistance level sits at $30.97. If the price goes on to break the first support level at $27.83, it is likely to go to the next support level at $26.90. The third support level lies at $26.26 if the price breaches the second support level.
Verona Pharma Plc ADR (NASDAQ: VRNA) Key Stats
With a market capitalization of 2.33 billion, the company has a total of 79,940K Shares Outstanding. Currently, annual sales are 0 K while annual income is -54,370 K. The company’s previous quarter sales were 0 K while its latest quarter income was -70,840 K.
